Overview

Details

Support

Prescribing Information & Adverse Events

Overview

Details

Support

Prescribing Information & Adverse Events

DaTSCAN™ (Ioflupane ¹²³I)

DaTSCAN™ (Ioflupane ¹²³I) injection is a radiopharmaceutical indicated for striatal dopamine transporter (DaT) visualization using single-photon emission computed tomography (SPECT) brain imaging in adult patients with clinically uncertain Parkisonian syndromes (CUPS) and it also helps to differentiate dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD).¹

Adverse events reporting

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GE HealthCare at
gpv.drugsafety@gehealthcare.com

At a glance

Pioneer and leader in DaT SPECT imaging

A pioneer and leader in DaT SPECT imaging, supported by more than two decades of data demonstrating clinical value that may aid in diagnosis.^2-6

Visualisation & Quantification

DaTQUANT can bring objectivity and enhance confidence in DaTSCAN image assessment.

Proven operational excellence

With over 20 years of experience in manufacturing and distributing DaTSCAN, we have established a reliable global supply chain.⁷

Commited to supporting Neuro-imaging community

Continued investment in R&D, participation in key neurology conferences, and provision of symposia and webinars

Confidence in the vial and far beyond

DaTSCAN (loflupane ¹²³I ) is a radiopharmaceutical used in a brain scan (SPECT) to visualize striatal dopamine transporters assisting in the evaluation of patients with Clinically Uncertain Parkinsonian Syndromes (CUPS) and patient with Probable Dementia with Lewy Body(DLB). DaTSCAN does not replace the physician's clinical diagnosis, but may help support the clinical evaluation and diagnostic confidence.¹

Confidence in Numbers

25+

years in across Europe.

>2.5 M

DaTSCAN scans have been performed⁸

98%

Of vial shipments were successfully delivered on time from our Eindhoven site from 2022 to 2025.⁷

Download DaTQUANT 2.01 for PC

Test drive DaTQUANT 2.01

Prior to purchase, test drive DaTQUANT 2.01 by downloading, installing and processing the included example studies. Import and processing of site data requires purchase of a license for DaTQUANT 2.01.

Visit DaTQUANT website >

To purchase DaTQUANT 2.01 To purchase a license for DaTQUANT 2.01, please click below on the contact us button to get in touch with your account manager.

Contact Us >

datquant_brain_feature_hero_desktop_1650x1100px

BENEFITS

Find out about our UK back-up reporting service

DaTSCAN studies are assessed visiually with or without quantification but on occasion can be difficult to interpret.The raw data is processed for visual assessment and quantification is used to provide a second opinion by an experienced Nuclear Medicine physician. Please note, there is a charge for this service.

To find out more about obtaining a back-up report, please email backup.reportUKI@gehealthcare.com

DIAGNOSTIC CLARITY

Quantitative analysis of DaTSCAN (Ioflupane ¹²³I) images at your fingertips

The DaTQUANT Software application enables visual evaluation and quantification of Ioflupane ¹²³I (DaTSCAN) images. Learn more how this application may assist in your evaluation of patients with a suspected Parkinsonian Syndrome and Dementia with Lewy Body (DLB).

Learn more

datquant_woman_feature_hero_desktop1650x1100px

OPERATIONAL EXCELLENCE

Precise supply chain from dose to delivery

• In Eindhoven, DaTSCAN production capacity has increased by 12% over the past five years.⁷

REFERENCES

1. DaTSCAN Summary of Product Characteristics UK
2. Booij J et al. J Nuc Med 2017,58: 1821-6
3 Catafau AM, et al. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004 Apr 22; 19(10): 1175-1182.
4. Kupsch AR, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012 Apr 6; 83(6):620-628.
5. Bajaj N, et al. Association between Hoehn and Yahr, mini-mental state examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes. Alzheimers Res Ther. 2014 Oct 8; 6(5-8): 67.
6. Bega D et al. NPJ Parkinsons Dis 2021; 7(1): 43.
7. GE HealthCare- Data on file- Supply chain data, May 2026

8. GE HealthCare- Data on file- DaTSCAN doses, October 2025

We’re sorry, a problem occurred with the form. Please try again.

Thank you!

We received your request for assistance.

A GE Healthcare specialist will be reaching out shortly.

Something went wrong

We will check and get back.

Try Again

JB04940UK July 2026